A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 311
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PDE5i
Long Form : phosphodiesterase type 5 inhibitors
No. Year Title Co-occurring Abbreviation
2020 Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue. ED
2020 Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. CI, ED, IIEF, IPSS, LUTS, MDs, PRISMA, PVR
2020 Comparative efficacy and safety of drug treatment for premature ejaculation: A systemic review and Bayesian network meta-analysis. ---
2020 Correcting imbalance of sex hormones by a phosphodiesterase 5 inhibitor improves copulatory dysfunction in male rats with type 2 diabetes. LETO, LH, OLETF
2020 Do Urologists Really Recognize the Association Between Erectile Dysfunction and Cardiovascular Disease? CVDs, ED
2020 Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis. ---
2020 Erectile Dysfunction after Kidney Transplantation. ---
2020 Evaluation of combined therapeutic effects of hydrogen sulfide donor sodium hydrogen sulfide and phosphodiesterase type-5 inhibitor tadalafil on erectile dysfunction in a partially bladder outlet obstructed rat model. ED, NOS, PBOO
2020 Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015. ORs, PH, VA
10  2020 Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. GDF15, RRS
11  2020 Isolation and characterization of N-hydroxyethyl dithio-desethyl carbodenafil from a health supplement. FTIR, HPLC-UV, HRMS, NMR
12  2020 Isolation and identification of ten new sildenafil derivatives in an alleged herbal supplement for sexual enhancement. ---
13  2020 Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders. ED, EHS, IIEF-EF, Li-SWT
14  2020 Low intensity shockwave therapy in combination with phosphodiesterase-5 inhibitors is an effective and safe treatment option in patients with vasculogenic ED who are PDE5i non-responders: a multicenter single-arm clinical trial. ED, Li-ESWT, PDU
15  2020 Management of erectile disfunction following robot-assisted radical prostatectomy: a systematic review. RARP
16  2020 PDE-5i Management of Erectile Dysfunction After Rectal Surgery: A Systematic Review Focusing on Treatment Efficacy. ED, IBD, IIEF, VEDs
17  2020 Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. 5ARI, BPH, LUTS
18  2020 Phosphodiesterases 5 inhibitors and erectile dysfunction recovery after pelvic surgery: future perspectives for new drugs and new formulations. ED
19  2020 Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis. ED, PRISMA
20  2020 Reliable screening and classification of phosphodiesterase type 5 inhibitors in dietary supplements using gas chromatography / mass spectrometry combined with specific common ions. DA, ECICs, EI, GC-MS, TMS
21  2020 Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension. ERS, ESC, MAPD, PAH
22  2020 Role of identified noncoding RNA in erectile dysfunction. ED, lncRNAs, miRNAs, ncRNAs
23  2020 Sildenafil Reduces Expression and Release of IL-6 and IL-8 Induced by Reactive Oxygen Species in Systemic Sclerosis Fibroblasts. ROS, RP, SSc
24  2020 Study of phosphodiesterase 5 inhibitors and alpha-adrenoceptor antagonists used alone or in combination for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. ABs, BPH, IIEF-EF, IPSS, LUTS, PVR, QOL
25  2020 Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study. PAH
26  2020 Testosterone Therapy in Relation to Prostate Cancer in a U.S. Commercial Insurance Claims Database. CI, HIRD, IRR, TT
27  2020 The Association of Phosphodiesterase 5 Inhibitor on Ischemia-Reperfusion Induced Kidney Injury in Rats. ICAM-1, IR, MCP-1
28  2020 The effect of tadalafil on reepithelialization and scarring of partial thickness porcine burns. ---
29  2020 The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). DU, ERAs, PAH, SRC, SSc-DU
30  2020 The medical and surgical treatment of erectile dysfunction: a review and update. ED
31  2020 The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species. ROS, SSc
32  2020 The Role of Testosterone in Amplifying the Effect of a Phosphodiesterase Type 5 Inhibitor After Pelvic Irradiation. eNOS, nNOS
33  2020 The Role of the Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Radical Prostatectomy: A Randomized Clinical Trial. ED, Li-ESWT, RP
34  2020 Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives. CTEPH, PAH, PEA, PH, sGC
35  2020 Undiagnosed prediabetes status is associated with a reduced effectiveness of phosphodiesterase type 5 inhibitors in men with erectile dysfunction. CCI, DM, ED, IIEF, MCID, TT
36  2020 [Pulmonary arterial hypertension (PAH ) : a new era of pulmonary arterial vasodilatators]. cGMP, ERA, PAH
37  2019 A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis. BPH, control-tadalafil, LUTS, NBP, NBP-tadalafil, S/E
38  2019 A purely penoscrotal approach: Reservoir placement of an inflatable penile prosthesis (IPP) in an orthotopic neobladder patient. Case report. IPP, PGE2
39  2019 Acute Hemodynamic Changes after Single Administration of Udenafil in Pulmonary Arterial Hypertension: a Phase IIa Study. CI, mPAP, MSAP, PAH, PAWP, PVRI
40  2019 An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction. ED, ICI
41  2019 Androgen Deficiency and Phosphodiesterase Type 5 Expression Changes in Aging Male: Therapeutic Implications. ED, LOH, NO, TRT
42  2019 Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models. PD, SERMs
43  2019 Carotid artery intima-media thickness can predict the response of patients with erectile dysfunction to phosphodiesterase 5 inhibitors. CCA, ED, IMT, ROC
44  2019 Co-Morbid Erectile Dysfunction (ED) and Antidepressant Treatment in a Patient - A Management Challenge? AD, ED, SD, SNRI, SSRI, TCA
45  2019 Current diagnosis and management of erectile dysfunction. ED
46  2019 Development of a specific fragment pattern-based quadrupole-Orbitrap mass spectrometry method to screen adulterated products of phosphodiesterase-5 inhibitors and their analogues. ED
47  2019 Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction? ED
48  2019 Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: a cost-effectiveness analysis. ED, ICI, IPP, QALYs
49  2019 Erectile Dysfunction Medications and Skin Cancer: An Analysis in US Veterans. BCC, MM, SD
50  2019 Evaluation of Clinical Outcomes with Phosphodiesterase-5 Inhibitor Therapy for Right Ventricular Dysfunction After Left Ventricular Assist Device Implantation. LVAD, PS, RV
51  2019 High rates of medication adherence in patients with pulmonary arterial hypertension: An integrated specialty pharmacy approach. AE, OOP, PAH, PDC
52  2019 Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction in Diabetic Patients. ED, IIEF-EF, Li-ESWT, SW
53  2019 Low-intensity shock wave therapy ameliorates erectile dysfunction in men with pelvic fractures associated with urethral injury. ED, EHS, IIEF-5, LiSWT, PFUI
54  2019 Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity. ERA, HRQoL, MCS, PAH, PCS
55  2019 Misdiagnosis And Undertreatment Of Erectile Dysfunction In The Portuguese Primary Health Care. ED
56  2019 Oncological and functional outcomes of robot-assisted radical cystectomy in bladder cancer patients in a single tertiary center: Can these be preserved throughout the learning curve? ECUD, ICUD, RARC
57  2019 PDE5 Inhibition Stimulates Tie2-Expressing Monocytes and Angiopoietin-1 Restoring Angiogenic Homeostasis in Diabetes. Ang-1, T2DM, TEMs
58  2019 Practical management of riociguat in patients with pulmonary arterial hypertension. PAH
59  2019 Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation. LVAD, OR, RHF, RV
60  2019 Safety and efficacy characteristics of oral drugs in patients with premature ejaculation: a Bayesian network meta-analysis of randomized controlled trials. CrI, ORs, PE, SMD
61  2019 Sildenafil, a phosphodiesterase type 5 inhibitor, augments sphincter bursting and bladder afferent activity to enhance storage function and voiding efficiency in mice. DAPM, EUS, LUT
62  2019 Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails. ED, EFD, IIEF, RCTs
63  2019 The Complex Relationship Between Lower Urinary Tract Symptoms and Sexual Health. BPH, LUTS
64  2019 The effect of CPAP and PDE5i on erectile function in men with obstructive sleep apnea and erectile dysfunction: A systematic review and meta-analysis. CPAP, ED, IIEF, NPR, NPTC, OSA, SAIR, TEE
65  2019 The Effect of Phosphodiesterase 5 Inhibitor on Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer. BCR, PCa, RP
66  2019 The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction. AUC, CNCI, ICP, LIMK2i, MAP, SM
67  2019 Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway. ERAs, NO, PAH
68  2019 Treatment patterns, healthcare resource utilization, and healthcare costs among patients with pulmonary arterial hypertension in a real-world US database. ERAs, PAH
69  2019 What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis. 6MWD, AEs, CI, ERAs, ES, FC, PAH-SDT, WMD
70  2019 [Tadalafil 5 mg once daily is a rationale option for simultaneous treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction]. BPH, ED, LUTS
71  2018 A review of synthetic phosphodiesterase type 5 inhibitors (PDE-5i) found as adulterants in dietary supplements. ESI-MSn, HPLC, MS, NMR, UV
72  2018 Anterior Ischemic Optic Neuropathy in a Patient with Erectile Dysfunction: Tadalafil as an Offending Medication. ED
73  2018 Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review. ---
74  2018 Comparative efficacy and safety of phosphodiesterase-5 inhibitors with selective serotonin reuptake inhibitors in men with premature ejaculation: A systematic review and Bayesian network meta-analysis. AEs, IVELT, NMA, PE, SSRI
75  2018 Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis. CHF, LVEF, mPAP, PASP, PH, PH-LDH, PVR, RCTs
76  2018 Efficacy and safety of low-intensity shock wave therapy in penile rehabilitation post nerve-sparing radical cystoprostatectomy: a randomized controlled trial. Li-ESWT, NS-RCP, PR
77  2018 Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension. ERA, PAH, QOL
78  2018 Longitudinal recovery patterns of penile length and the underexplored benefit of long-term phosphodiesterase-5 inhibitor use after radical prostatectomy. CR, EF, IR, PL, RP
79  2018 Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial. CL, HR, PAH
80  2018 Mechanisms Involved in the Remyelinating Effect of Sildenafil. BMDM, cGMP, CNS, CNTF, EAE, MOG, MS, NO, OLs
81  2018 Oral L-citrulline and Transresveratrol Supplementation Improves Erectile Function in Men With Phosphodiesterase 5 Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study. AMS-SD, ED, EHS, SHIM
82  2018 Penile rehabilitation for postprostatectomy erectile dysfunction. CI, Grey Literature Report, IIEF-EF, RR
83  2018 Phosphodiesterase-5 Is Elevated in Failing Single Ventricle Myocardium and Affects Cardiomyocyte Remodeling In Vitro. SV
84  2018 Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH. CTEPH, PAH, PH
85  2018 Scrotal hemorrhage after testicular sperm aspiration may be associated with phosphodiesterase-5 inhibitor administration: a retrospective study. TESA
86  2018 Sexual Rehabilitation After Nerve-Sparing Radical Prostatectomy: Free-of-Charge Phosphodiesterase Type 5 Inhibitor Administration Improves Compliance to Treatment. EDITS, NSRP, PDE5I-F, UCLA-PCI-s
87  2018 Sildenafil ameliorates EAE by decreasing apoptosis in the spinal cord of C57BL/6 mice. EAE, MS
88  2018 Sildenafil in Left Ventricular Assist Device Is Safe and Well-Tolerated. GI, HF, LVAD, OHT
89  2018 Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. CI, ERA, FC, HRs, PAH, WHO
90  2018 The Phosphodiasterase 5-Inhibitors (PDE-5i) for Erectile Dysfunction (ED): A Therapeutic Challenge For Psychiatrists. ED, EF, GMP, PE, SI
91  2018 Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. BPH, ED, LUTS
92  2018 [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction]. BPH, ED, LUTS
93  2017 A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension. AEs, ERA, NO, PAH
94  2017 Acute tadalafil administration increases plasma fatty acids without changes in the inflammatory response in healthy men. FFAs, IL-10, IL-6, IL-8, TNF-alpha
95  2017 Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. BDI, BNP, CMRI, FC, PAH
96  2017 Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension. CP, CPX, ERA, PAH, SBP, VP
97  2017 Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease. ERA, ES
98  2017 Efficacy of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi: A systematic review and meta-analysis. CI, MET, RD
99  2017 Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy. NAION
100  2017 Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis. EF, NSRP, RCTs, SEP-3